Our Research Summary

Tikun Olam for us is bringing a cure and relief to patients. Research and development are integral to fulfilling our vision. 

Alongside outstanding results and success of treatment, we work and dedicate a great deal of time and effort in order to examine the efficiency and safety of our products; through constant follow-up with patients, laboratory studies, both invitro and in-vivo, retrospective studies, surveys and clinical interventional research (as detailed below).

After treating over 20,000 patients, we're now holding the most extensive patient treatment database in the field of medical cannabis anywhere in the world.

 Our proprietary strains and products are examined and distributed as treatment for various diseases and symptoms.

We initiate and sustain partnerships and industrial relations with physicians, scientists and heads of departments of leading medical institutions.

Our chief scientist is Professor Zvi Bentwich - a leading AIDS researcher, board member of Physicians for Human Rights, and one of the first doctors to treat with medical cannabis in Israel.


Below the status of the studies:


1. Treatment of Crohn’s Disease with Cannabis- An Observational Study:

The retrospective research study was conducted by interviewing patients suffering from  Crohn’s disease.The study has found very positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, blood in stool samples, pain, etc.).

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

Published in: IMAJ - The Israel Medical Association Journal, 2011

To download the full study click here

2. Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Randomized Placebo-Controlled, Double-Blind Study:

In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam's Erez strain to produce dramatic results with 50% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed. 

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

Published in: Clinica Gastroenterology& Hepatology 2013

To download the full study click here

3. The Anti-Inflammation and Anti-Pain Properties of Cannabis Extracts:

Laboratory research study that was conducted on rodents which examines the effect of extractions of the main strains developed by Tikun Olam on inflammation and pain, in comparison with placebo and isolated CBD.

Verification of strong effectiveness of Avidekel (in comparison to infection counteracting medicines Tramadol and Asperin) as well as a strong reactive strength in comparison to the administration of pure CBD.

Head Researcher: Prof. Ruth Gallily

Hospital: Hadassah University Hospital-Ein Kerem, Jerusalem, Israel

Published in: Pharmacology & Pharmacy, 2015, 6, 75‐85 

Full article 

4.The Effects of Cannabis on Appetite and Blood Indices of Geriatric Patients:

A long-term observational follow-up conducted to collect data from elderly nursing home patients that regularly use medical cannabis. The study measures parameters such as: nutritional blood work, caloric intake, weight, prescription drug usage, sepsis, trembling, spasticity, and quality of life measurements (mood, sleeping habits, etc.)

Head Researcher: Dr. Moshe Geitzen, Geriatrics

Location: Hadarim Nursing Home, Kibbutz Naan

Treating elderly with medical cannbais- special project, Tikun olam has accumulated data on a unique three year (2009-2013) research of treating old age with Tikun Olam Medical Cannabis strains and products in "Hadarim" Nursing Home. The project in "Hadarim" nursing home in kibbutz Na'an has finished and the results and data are helping treat the elderly in Israel, Canada and hopefully in the future the rest of the world. 

5. The Effects of Cannabis on Parkinson's Disorders:

The study is a research survey through questionnaires that examines the effects of cannabis on the motor and  non- motor symptoms, of patients with different movement disorders (Parkinson’s disease, Parkinson plus syndromes, dystonia, tics and Tourette syndrome and others) , including quality of life and activity of daily living as well as  the side effects resulting from the cannabis consumption. 

76.9% reported positive effect on their general condition and mood, 64% reported improvement in pain and spasticity, 59% reported decreased tremors and improved quality of sleep.

Head Researcher: Dr. Tanya Gurevich, Movement Disorders Unit

Hospital: Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Published in Clinical Neuropharmacology: November/December 2017 - Volume 40 - Issue 6 - p 268–272



1. Effects of Avidekel on Dystonia and Spasticity of Cerebral Palsy Paediatric Patients

Clinical random trial examined the effects of Avidekel oil on dystonia and spasticity in children who suffer from CP or genetic impairment.

Results have shown significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and quality of life was observed.  Adverse effect included worsening of seizures in two patients; behavioral changes in two patients; somnolence in one patient.

Head ResearcherDr. Luba Blumkin, Wolfson Hospital

2. Effects of Cannabis on children diagnosed with ASD (Autistic spectrum disorder)

Retrospective cohort study of 53 patients. study product: Avidekel oil 1:20 and Erez oil 3%

The patients showed 75% improvement in ASD comorbidities symptoms.

Dr. Orit Stoler, Assaf Harofeh Medical Center

3. Effects of Medical Cannabis on Children and Adolescents with Epilepsy:

Retrospective cohort study of 74 patients.The purpose of the study to describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil including Abidkl  oil 1:20.

Results: most of the patients (66/74, 89%) reported some reduction in seizure frequency.

Chief Researcher: Dr. Michal Zadok

Medical centers: Sheba, Sourasky, Wolfson, Assaf Harofeh, MCU MOH

To download the full study click here



1.The Effects of Cannabis on Colitis:

Clinical research comparing a group of patients who will be given “Erez” strain cannabis cigarettes (0.5 grams per cigarette) and a group of patients who will be given placebo cigarettes (a total of two cigarettes per day) for a period of eight weeks, during which the effect of the substance on blood inflammation indices, life quality, medicine consumption, and adverse side effects etc., will be monitored.

Head Researcher:  Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

2. The Effects of Cannabis on Crohn's Disease:

Clinical research comparing a test group, receiving the Avidekel strain, and a control group (placebo), in order to examine the effect of cannabis administered with oil on the inflammatory intestinal disease. The oil contains a high concentration of CBD (200 mg) and a low concentration of THC (59 mg) and is administered twice a day.

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

4. Cannabis and IBD Data Collection:

Large-scale long-term data collection study on patients with a permit for medical cannabis that suffer from inflammatory bowel disease (IBD) to determine the effect of cannabis use on the symptoms and adverse side effects of the disease over a long time period. The study will look at different ingestion methods and various cannabis strains to determine their impact.

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel



The Effects of Cannabis on Immune Response:

The effect of Extracts of Avidekel, Erez and Midnight on immune response in blood samples in which infection was induced.

Verification of a suppressing effect of natural cannabinoids on the release of inflammation triggering cytokines; indication of a possible inflammation preventing effect of CBD on the immune system.

Head ResearcherDr. Yishay Sekely

HospitalTel Aviv Sourasky